• Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens
  • A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas
  • AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount
  • Dividend Investing Newsletter and model portfolio that focuses on dividend growth
  • AAII Growth Investing Find secular growth stocks poised for outperformance regardless of macroeconomic conditions.
  • Retirement Investing Discover trusted strategies for every stage of retirement. Get actionable insights and resources for smart retirement planning.
  • Sentiment Investing A research-driven newsletter with 10+ signals decoding sentiment across retail and institutional behavior.
  • Stock Superstars Report Get stock ideas inspired by the market's leading professionals
  • VMQ Stocks For the value investor looking to harness academic research in an actively managed portfolio
  • Bits and Bips Newsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Explore All Membership Options
Join Now

Stock Evaluator: Connect Biopharma Holdings Limited (CNTB)

Connect Biopharma Holdings Limited CNTB

$0.76 -0.04 -4.51%
October 22, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,070,809
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Commentary & Analysis

Financial Summary

Share Statistics CNTB Industry
Median		 Percentile
(All Stocks)
Market Cap (Mil) $48.0 $229.3 16%
Shares Out (Mil) 62.9 53.4 53%
Institutional Ownership 56.0% 92.9% 38%
Float (Mil) 17.3 41.4 27%
Beta na 0.94 na
Avg Daily Volume (000s) 1,164 533 73%
Price Change
(52-week)		 (54.9%) 47.5% 18%
Growth CNTB Industry
Median		 Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) 14.2% (10.1%) 62%
EPS (5yr) 32.2% 15.8% 83
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (15.1%) (15.7%) 51%
Estimates Qtrly Current
Fiscal
Year		 Next
Fiscal
Year
# of Estimates 5 5 5
Current EPS ($0.258) ($0.976) ($0.772)
Month Ago EPS ($0.254) ($0.968) ($0.698)
# Rev Up 0 3 2
# Rev Down 0 0 0
Three Months Ago EPS ($0.277) ($1.058) ($0.817)
Year/Year Chg (6.2%) (2.1%) (43.0%)
Financials CNTB Industry
Median		 Percentile
(All Stocks)
Sales (TTM) (Mil) $3 $37 4%
Net Income (TTM) (Mil) ($69) ($44) 14%
EPS (TTM) ($1.193) ($1.600) 20%
Operating Cash Flow (TTM) (Mil) ($61) ($34) 9%
Net Cash Flow (TTM) (Mil) ($14) $3 29%
Long-Term Debt (Q1) (Mil) $0 $4 12%
Enterprise Value (Q1) (Mil) $129 $179 23%
Valuation CNTB Industry
Median		 Percentile
(All Stocks)
P/B 1.77 2.17 49%
P/E na 20.3 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.2 na
Ratios CNTB Industry
Median		 Percentile
(All Stocks)
Gross Margin 100.0% 66.0% 96%
Net Margin na (75.3%) na
ROA (109.3%) (47.1%) 5%
ROE (140.5%) (53.5%) 6%
Liabilities to Assets 38.2% 29.3% 29%
F-Score 2 2 7%

Connect Biopharma Holdings Limited did not pass any screens on 10/22/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors